ETHIQA XR® PUBLICATIONS
Extended-release buprenorphine, an FDA-indexed analgesic, attenuates mechanical hypersensitivity in rats.
Alamaw, E. D., Franco, B., Jampachaisri, K., Huss, M. K., & Pacharinsak, C. (2021). Extended-Release Buprenorphine, an FDA-indexed Analgesic, Attenuates Mechanical Hypersensitivity in Rats. Journal of the American Association for Laboratory Animal Science, 60(5), 314. Poster presented at AALAS National Conference, October 2021; Kansas City, MO.
Extended-release buprenorphine, an FDA-indexed analgesic, attenuates mechanical hypersensitivity in rats (rattus norvegicus).
J Arthur, ED Alamaw, K Jampachaisri, C Nagamine, MK Huss, C Pacharinsak Institution(s): Department of Comparative Medicine, Stanford University, Stanford, CA; Faculty of Science, Naresuan University, Phitsanulok, Thailand. Poster presented at AALAS National Conference, October 2021; Kansas City, MO.
Assessment of the Safety and Efficacy of Pre-emptive Use of Extended-release Buprenorphine for Mouse Laparotomy.
Chan G, Si C, Nichols MR, Kennedy L. Assessment of the Safety and Efficacy of Pre-emptive Use of Extended-release Buprenorphine for Mouse Laparotomy. J Am Assoc Lab Anim Sci. 2022 Jul 1;61(4):381-387. doi: 10.30802/AALAS-JAALAS-22-000021. Epub 2022 Jul 8. PMID: 35803705; PMCID: PMC9674008.
Huss MK, Pacharinsak C. A Review of Long-acting Parenteral Analgesics for Mice and Rats. J Am Assoc Lab Anim Sci. 2022 Nov 1;61(6):595-602. doi: 10.30802/AALAS-JAALAS-22-000061. Epub 2022 Nov 15. PMID: 36379476; PMCID: PMC9732779.
Comparative Pharmacokinetics and Injection Site Histopathology in Nude Mice Treated with Long-acting Buprenorphine Formulations
Pharmacokinetic and histopathologic study of an extended-release, injectable formulation of buprenorphine in Sprague–Dawley rats.
Levinson, B. L., Leary, S. L., Bassett, B. J., Cook, C. J., Gorman, G. S., & Coward, L. U. (2021). Pharmacokinetic and Histopathologic Study of an Extended-Release, Injectable Formulation of Buprenorphine in Sprague–Dawley Rats. Journal of the American Association for Laboratory Animal Science, 60(4), 462–469. doi: 10.30802/AALAS-JAALAS-20-000149
Efficacy and duration of various buprenorphine preparations in a mouse hind paw incision model of pain.
Mangosing, S. J., Martin, H. R., Lieggi, C., Willis, D. E., & Lipman, N. S. (2021). Efficacy and Duration of Various Buprenorphine Preparations in a Mouse Hind Paw Incision Model of Pain. Abstracts of Scientific Papers 2021 AALAS National Meeting, P350.
Lipid bound extended-release buprenorphine effectively attenuates post-operative hypersensitivity in an incisional pain model in mice (mus musculus).
Navarro, K., Jampachaisri, K., Huss, M., & Pacharinsak, C. (2020). Lipid Bound Extended-release Buprenorphine Effectively Attenuates Postoperative Hypersensitivity in an Incisional Pain Model in Mice (Mus musculus). Abstracts of Scientific Papers 2020 AALAS National Meeting, P105.
Lipid bound extended-release buprenorphine (high and low doses) and sustained release buprenorphine effectively attenuate post-operative hypersensitivity in an incisional pain model in mice (mus musculus).
Navarro, K., Jampachaisri, K., Huss, M., & Pacharinsak, C. (2021). Lipid bound extended release buprenorphine (high and low doses) and sustained release buprenorphine effectively attenuate post-operative hypersensitivity in an incisional pain model in mice (Mus musculus). Animal Models and Experimental Medicine, 4(2), 129-137. https://doi.org/10.1002/ame2.12157
Saenz, M., Bloom-Saldana, E. A., Fueger, P. T., Ermel, R., & Finlay, J. (2020). Postsurgical Recovery Assessment of Mice Treated with Extended- or Sustained-Release Buprenorphine. Abstracts of Scientific Papers 2020 AALAS National Meeting, P342.
Pharmacokinetics of sustained-release buprenorphine and extended-release buprenorphine in mice with surgical catheterization.
Saenz M, Bloom-Saldana E, Synold T, et al. Published online March 17, 2022.
Extended-release buprenorphine effectively attenuates laser-induced thermal hypersensitivity in an incisional model in neonatal rats.
Zhang, M., Alamaw, E. D., Jampachaisri, K., Huss, M. K., & Pacharinsak, C. (2021). Extended Release Buprenorphine Effectively Attenuates Laser-Induced Thermal Hypersensitivity in an Incisional Model in Neonatal Rats. In Abstracts of Scientific Papers 2021 AALAS National Meeting, P338. Stanford University, Cupertino, CA; Department of Mathematics, Naresuan University, Phitsanulok, Thailand. AALAS National Meeting. (2021). Title of the Abstract. In Abstracts of Scientific Papers 2021 AALAS National Meeting, P338.
PUBLICATIONS ON ANIMALGESIC
Laudadio, V., Guarnieri, M., Brayton, C., Sarabia-Estrada, R., Tyler, B., McKnight, P., & DeTolla, L. (2017). Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats. Journal of Veterinary Medicine, 2017, 4:1-11., 3102567.
Guarnieri M, Brayton C, Tyler BM. Published online July 9, 2018. doi: 10.1155/2018/2616152
Itzoe ML, Ye X, Sarabia-Estrada R, et al. Int J Res Health Sci. 2018;6(1):2169-2177.
Sarabia-Estrada R, Cowan A, Tyler BM, Guarnieri M. Lab Animal. 2017;46:242-244.
Schildhaus N, Trink E, Polson C, et al. J Pharm Bioallied Sci. 2014;6(1)43-47.
Traul KA, Romero JB, Brayton C, DeTolla L, Forbes-McBean N, Halquist MS, Karnes HT, Sarabia-Estrada R, Tomlinson MJ, Tyler BM, Ye X, Zadnik P, Guarnieri M. Safety studies of post-surgical buprenorphine therapy for mice. Lab Anim. 2015 Apr;49(2):100-10. doi: 10.1177/0023677214554216. Epub 2014 Oct 10. PMID: 25305141.
WARNING: ABUSE POTENTIAL and LIFE-THREATENING RESPIRATORY DEPRESSION and ACCIDENTAL EXPOSURE
Ethiqa XR contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of Ethiqa XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.
Do not dispense Ethiqa XR.
Life-Threatening Respiratory Depression
The concentration of buprenorphine in Ethiqa XR is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of Ethiqa XR. Ethiqa XR has additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids.
Important Safety Information
For Rats and Mice:
Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression.
Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans.
For more information, consult the prescribing information including the boxed warning.